CoreCap Advisors’s Novavax NVAX Stock Holding History

CoreCap Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405	Hold	43	–	–	﹤0.01%	2906
2026 Q1	$350	Hold	43	–	–	﹤0.01%	2701
2025 Q4	$289	Sell	43 -100	-70%	-$754	﹤0.01%	2771
2025 Q3	$1.24K	Hold	143	–	–	﹤0.01%	2446
2025 Q2	$901	Hold	143	–	–	﹤0.01%	2438
2025 Q1	$917	Hold	143	–	–	﹤0.01%	2544
2024 Q4	$1.15K	Hold	143	–	–	﹤0.01%	2355
2024 Q3	$1.81K	Buy	+143	New	+$1.85K	﹤0.01%	2190
2024 Q2	–	Sell	-143	Closed	-$684	–	2271
2024 Q1	$684	Buy	+143	New	+$663	﹤0.01%	2288
2022 Q4	$1.47K	Buy	+143	New	+$2.52K	﹤0.01%	1995
2022 Q3	–	Sell	-153	Closed	-$8K	–	1551
2022 Q2	$8K	Buy	+153	New	+$7.92K	﹤0.01%	1540
2022 Q1	–	Sell	-536	Closed	-$77K	–	1544
2021 Q4	$77K	Buy	+536	New	+$92.1K	0.01%	857

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

CoreCap Advisors's NVAX Position: Q2 2026 in Review

CoreCap Advisors held its Novavax (NVAX) position steady in Q2 2026 at 43 shares worth $405. The position accounts for ﹤0.01% of the portfolio, ranked #2906.

CoreCap Advisors first reported a position in NVAX in Q4 2021 and has held it in 12 quarters since. The position peaked at $77K in Q4 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

CoreCap Advisors held 43 shares of Novavax worth $405 as of Q2 2026.
CoreCap Advisors left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2906 holding.
CoreCap Advisors first reported a position in Novavax in Q4 2021 and has held it in 12 quarters since.
CoreCap Advisors's Novavax position peaked at $77K in Q4 2021.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.